CGEM news & sentiment — Cullinan Therapeutics, Inc.

DEC 9·Investing.comMed

H.C. Wainwright reiterates Buy rating on Cullinan Oncology stock at $24

H.C. Wainwright has reiterated its Buy rating and $24 price target for Cullinan Oncology (NASDAQ:CGEM) following updated positive data from its Phase 2b REZILIENT1 trial for zipalertinib in NSCLC patients. The stock is currently trading near its 52-week low but is considered undervalued by InvestingPro analysis based on its Fair Value metrics. This comes amidst other recent positive developments, including continued support from analysts despite competing drug approvals.

OCT 25·Benzinga

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025 - Cullinan Therapeutics ( NASDAQ:CGEM )

CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases

OCT 13·Benzinga

Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations - Cullinan Therapeutics ( NASDAQ:CGEM )

Taiho Oncology Inc. and Cullinan Therapeutics Inc. ( NASDAQ:CGEM ) shared new data on Sunday from the central nervous system ( CNS ) involvement cohort of the REZILIENT2 study of zipalertinib for advanced or metastatic non-small cell lung cancer ( NSCLC ) harboring EGFR exon 20 insertion ...

$CGEM

H.C. Wainwright reiterates Buy rating on Cullinan Oncology stock at $24

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025 - Cullinan Therapeutics ( NASDAQ:CGEM )

Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations - Cullinan Therapeutics ( NASDAQ:CGEM )

News on $CGEM